China-based biotech company ImmVira has entered into an exclusive partnership with compatriot firm China Resources Biopharmaceutical Co., Ltd to jointly develop MVR-C5252, a potential first-in-class oncolytic virus product for the treatment of gliomas and other central nervous system (CNS) tumors.
Product Details
MVR-C5252, developed using ImmVira’s OvPENS drug development platform, has been genetically engineered to selectively target and kill malignant glial cells while ensuring safety. As the only oncolytic virus product carrying and expressing specific therapeutic tumor target genes, MVR-C5252 aims to promote immune responses in the tumor microenvironment and enhance antitumor activity.
Disease Background
Gliomas, the most common CNS tumors, include highly malignant forms such as glioblastoma (GBM), which can occur in the brain or spinal cord. Current standard treatments include surgical resection and chemoradiotherapy, but the recurrence rate of gliomas is nearly 100%, with a median survival time of only 1.5 years. More effective treatment options are urgently needed.
Advantages of Oncolytic Viruses
Compared to other tumor immunotherapies, oncolytic viruses offer several advantages, including high killing efficiency, good targeting, fewer side effects, multiple tumor-killing pathways to avoid drug resistance, and lower costs. The partnership between ImmVira and China Resources Biopharmaceutical aims to leverage these benefits to develop a more effective treatment for gliomas and other CNS tumors.-Fineline Info & Tech
